Welcome to Xi’an Good Doctor Medical Science and Technology Co., Ltd.website ！
Internet Drug Information Service Qualification Certificate: (Shaanxi)-Non-Operating -2023-0143
Expert Consensus on the Design of an Interventional Clinical Study of Malignant Pleural Effusion
2025-07-10
CACA China Integrated Diagnosis and Treatment Guidelines for Peritoneal Tumors - 2025 Edition
Peritoneal tumors are mainly classified as primary and secondary. Primary tumors originate from the peritoneum; common types include primary peritoneal cancer (Müllerian-type epithelial tumors, mainly serous carcinoma) and malignant peritoneal mesothelioma (MPM). Secondary tumors include various metastatic cancers, peritoneal sarcomatosis (PS), pseudomyxoma peritonei (PMP), and gliomatosis. Clinically, metastatic and epithelial malignant peritoneal tumors are more common, while primary and mesenchymal tumors are relatively rare and considered rare diseases.
2025-07-10
Colorectal cancer is one of the most common malignant tumors in China, ranking second and fourth in incidence and mortality rates among all malignant tumors, respectively. Metastasis and recurrence are the main causes of death in patients with colorectal cancer. The peritoneum is a common site of colorectal cancer metastasis, second only to liver and lung metastasis, but its prognosis is far worse than that of liver and lung metastasis.
2025-07-10
【New Law】Application and Key Points of Thoracic Thermal Perfusion Chemotherapy in Thoracic Treatment
Malignant pleural effusions (MPEs) are mainly seen in patients with advanced lung cancer (37.5%), breast cancer (16.8%), lymphoma (11.5%), genitourinary malignancies (9.4%), and gastrointestinal malignancies (6.9%); the median overall survival time for patients with MPEs and pleural metastases is 3-4 months.
2025-07-10
Among gynecological malignancies, ovarian cancer has the most grim prognosis, primarily due to its high recurrence risk after treatment. Multiple recurrences lead to increased drug resistance. Recurrent ovarian cancer is classified into platinum-sensitive and platinum-resistant types, and treatment strategies depend on the patient's sensitivity to platinum-based chemotherapy. For patients with platinum-sensitive recurrent ovarian cancer, the use of platinum-based chemotherapy combined with targeted therapy (such as PARP inhibitors or bevacizumab) has been shown to prolong survival.
2025-07-10
Hyperthermic intraperitoneal chemotherapy (HIPEC) has been used to treat gastric cancer, but its efficacy in patients with peritoneal metastasis of ovarian cancer remains unclear, hindering the development of rational combination therapies based on hyperthermia (HT).
2025-07-09
The current study was designed to analyze safety of the bedside hyperthermic intra-pleural or intra-peritoneal chemotherapy (HIPEC) from September 2007 to July 2015. Total of 5,759 times of bedside HIPEC in 985 cases of malignant pleural or peritoneal carcinomatosis were analyzed.
2025-07-08
Lili Liu, Tao Zhang, Xiang Song, Cheng-gong Liao, Tengyun Xu, Yang Yang, Ming Zeng, Junmei Jia, Haichuan Su, Yang Song
2025-07-08
Thermal Chemotherapy for Tumors - Current Status and Prospects
Drug treatment for tumors, commonly known as chemotherapy, is currently one of the main methods for treating tumors. With the increasing incidence of malignant tumors, research in related fields is very active worldwide. The emergence of new drugs and the standardization and improvement of chemotherapy regimens have led to a certain degree of improvement in the survival rate and survival time of cancer patients.
2022-08-26
Clinical Analysis of Malignant Chest and Abdominal Cavity Hyperthermic Intraperitoneal Chemotherapy
Malignant pleural and abdominal effusion is one of the common clinical manifestations and serious complications of malignant tumors. Any malignant tumor can cause malignant pleural and abdominal effusion when it invades the thoracic or abdominal cavity. The treatment of malignant pleural and abdominal effusion can be divided into systemic and local treatment methods. For malignant tumors that are sensitive or relatively sensitive to chemotherapy, systemic chemotherapy can lead to malignant pleural effusion.
2022-08-26
· China Good Doctor ·
· Good friends of human beings ·
Address: Floor 1-2, Left Building No. 1, Huoju Road, East zone of Xi’an High- tech Development District, Xi’an, China
Copyright Xi'an Good Doctor Medical Technology Co., Ltd.
Internet Drug Information Service Qualification Certificate (Shaanxi)-Non-Operating -2023-0143